- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2023 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Bone Marrow & Stem Cell Transplant | Clinical
Preventing and Managing Cytomegalovirus After Hematopoietic Stem Cell Transplant
January 14, 2023
In an interview with Targeted Oncology, Guenther Koehne, MD, PhD provided a detailed explanation on the impact of cytomegalovirus reactivation post-transplant, cytomegalovirus reactivation prevention, and refractory cytomegalovirus reactivation.
The Use of Transplant in the Post CAR T Setting
January 11, 2023
Robert J. Soiffer, MD, discusses the role of transplant in the post chimeric antigen receptor setting for patients with hematologic malignancies.
Autologous HSCT Proves Superiority vs KCd Regimen in Multiple Myeloma
January 07, 2023
While upfront transplant showed benefit vs carfilzomib, cyclophosphamide, and dexamethasone in the phase 2 CARDAMON study of patients with multiple myeloma, 57.7% of patients achieved at least a very good partial response with the combination.
Allogeneic SCT Shows Efficacy in TP53+ AML and MDS
December 15, 2022
Melhem M. Solh, MD, discusses results of a study investigating allogeneic stem cell transplant in patients with myelodysplastic syndrome and acute myeloid leukemia with a TP53 mutation, previously presented at the 2022 Transplantation & Cellular Therapy Meetings.
Ten-Year Omidubicel Data Improves Survival in Hematologic Malignancies With HSCT
November 28, 2022
Favorable long-term survival rates and manageable rates of graft-vs-host disease were elicited with omidubicel in patients with hematologic malignancies who underwent allogeneic stem cell transplant.
Role of Transplant Across Hematologic Malignancies
November 15, 2022
Robert J. Soiffer, MD, discusses the use of transplant in various hematologic malignancies.
Best Uses of Transplantation for Patients With Peripheral T-Cell Lymphoma
November 15, 2022
Randomized studies examining patients with peripheral T-cell lymphoma regarding the role of transplant are lacking and more research is needed to personalize therapy for patients based on subtype, biomarkers, mutational profiling, and radiographic parameters.
Fatigue Not Linked With Treatment Intensity/Type in Patients With Pediatric Cancer and HSCT
October 10, 2022
More interventions are needed to address fatigue in survivors of cancer and hematopoietic stem cell transplant.
Mitigating Transplant-Induced GVHD
October 05, 2022
Salman Fazal, MD, explains how to lower the risk of graft-versus-host disease in patients who undergo allogeneic stem cell transplant.
Ponatinib/Blinatumomab Displays Efficacy as a Chemo-Free, HSCT-Sparing Option in Ph+ ALL
September 28, 2022
In an interview before the conference, Fadi G. Haddad, MD, discussed the updated results from the combination of blinatumomab and ponatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.